Investigational Drug Information for Beloranib
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug Beloranib?
Beloranib is an investigational drug.
There have been 8 clinical trials for Beloranib.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2014.
The most common disease conditions in clinical trials are Obesity, Prader-Willi Syndrome, and Overweight. The leading clinical trial sponsors are Zafgen, Inc. and [disabled in preview].
There are sixty-seven US patents protecting this investigational drug and seven hundred and eighty-eight international patents.
Summary for Beloranib
| US Patents | 67 |
| International Patents | 788 |
| US Patent Applications | 151 |
| WIPO Patent Applications | 84 |
| Japanese Patent Applications | 44 |
| Clinical Trial Progress | Phase 2 (2014-09-01) |
| Vendors | 19 |
Recent Clinical Trials for Beloranib
| Title | Sponsor | Phase |
|---|---|---|
| An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus | Zafgen, Inc. | Phase 2 |
| Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome | Zafgen, Inc. | Phase 3 |
| An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury | Zafgen, Inc. | Phase 2 |
Clinical Trial Summary for Beloranib
Top disease conditions for Beloranib
Top clinical trial sponsors for Beloranib
US Patents for Beloranib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Beloranib | See Plans and Pricing | METAP2 inhibitors and methods of treating obesity | SynDevRx, Inc. (Cambridge, MA) | See Plans and Pricing |
| Beloranib | See Plans and Pricing | Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome | Essentialis, Inc. (Redwood City, CA) | See Plans and Pricing |
| Beloranib | See Plans and Pricing | Anti-Laminin4 antibodies specific for LG4-5 | PROTHENA BIOSCIENCES LIMITED (Dublin, IE) | See Plans and Pricing |
| Beloranib | See Plans and Pricing | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | See Plans and Pricing |
| Beloranib | See Plans and Pricing | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk | ELCELYX THERAPEUTICS, INC. (San Diego, CA) | See Plans and Pricing |
| Beloranib | See Plans and Pricing | ACC inhibitors and uses thereof | Gilead Apollo, LLC (Foster City, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Beloranib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Beloranib | Argentina | AR095828 | 2033-04-10 | See Plans and Pricing |
| Beloranib | Australia | AU2014250983 | 2033-04-10 | See Plans and Pricing |
| Beloranib | Brazil | BR112015025892 | 2033-04-10 | See Plans and Pricing |
| Beloranib | Canada | CA2908993 | 2033-04-10 | See Plans and Pricing |
| Beloranib | China | CN105431426 | 2033-04-10 | See Plans and Pricing |
| Beloranib | China | CN112494476 | 2033-04-10 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
